Abstract
In press
Background. Medication-resistant arterial hypertension in people aged 10–30 years is clinically important because persistent blood pressure elevation is associated with early target-organ damage and long-term cardiovascular risk.
Aim. To examine current approaches to the prevention and treatment of medication-resistant hypertension in people aged 10–30 years, including non-pharmacological and pharmacological strategies and transdisciplinary models of care.
Materials and Methods. This article presents a narrative review of the scientific literature of the past 10 years retrieved from the PubMed, Scopus and Web of Science databases. Inclusion criteria were English-language peer-reviewed clinical and cohort studies, randomized controlled trials, clinical guidelines, systematic reviews, and directly relevant narrative reviews addressing people aged 10–30 years; adult-only studies without applicability to this age range, conference abstracts without full text, and non-peer-reviewed material were excluded. The study was conducted as a private initiative of the authors, without grant support or state registration of the research topic.
Research Ethics. The review analyzed only published data whose authors declared compliance with ethical standards.
Results. Resistant hypertension was treated as an age-specific phenotype: adult criteria require at least three drugs of different classes, including a diuretic, at maximally tolerated doses with confirmation of uncontrolled values outside the clinic, whereas pediatric criteria are percentile-based. Pseudoresistance caused by non-adherence, the white-coat effect, and measurement error has to be excluded first. Obesity, short sleep, high sodium intake, energy-drink consumption, marked prematurity, and very low birth weight are identifiable contributors, while renal, renovascular and endocrine secondary causes require targeted evaluation. Lifestyle modification and age-adapted pharmacotherapy are supported, but evidence or direct intervention in this age range remains limited.
Conclusions. The aim was achieved: transdisciplinary approaches to the prevention, diagnosis, and treatment of medication-resistant arterial hypertension among people aged 10–30 years were identified and systematized. Diagnostic verification precedes the diagnosis of true resistance; secondary and pseudoresistant forms require targeted evaluation; transdisciplinary care is justified as an organizational framework, although comparative studies are lacking.
Keywords: cardiology, juvenile hypertension, pediatric blood pressure, renin-angiotensin-aldosterone system.
References
Hamrahian SM, Falkner B. Approach to hypertension in adolescents and young adults. Curr Cardiol Rep. 2022;24(2):131-40. DOI: 10.1007/s11886-021-01632-x. PMID: 35000150.
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. DOI: 10.1093/eurheartj/ehae178. PMID: 39210715.
Camafort M, Kreutz R, Cho M-C. Diagnosis and management of resistant hypertension. Heart. 2024;110(22):1336-42. DOI: 10.1136/heartjnl-2022-321730. PMID: 38135468.
Bourque G, Hiremath S. Rethinking resistant hypertension. J Clin Med. 2022;11(5):1455. DOI: 10.3390/jcm11051455. PMID: 35268545.
Kulbachuk OS, Dmytrieva SM, Sid YV, Solovyov OV, Piskun AV. Dynamics of endothelial function biomarker levels in patients with treatment-resistant hypertension under the influence of treatment. Ukr J Med Biol Sport. 2022;7(4):41-7. DOI: 10.26693/jmbs07.04.041. [In Ukrainian].
Naydenov S, Manov E, Runev N. Prevalence, clinical characteristics, and treatment of patients with resistant hypertension: a single-center study. J Cardiovasc Dev Dis. 2024;11(9):279. DOI: 10.3390/jcdd11090279. PMID: 39330337.
Kennedy C, Ali O, Farnan R, Stinson J, Gabr A, Hall M, et al. Clinical characteristics of two groups commonly referred to an Irish hypertension service: patients with resistant hypertension and young adults with hypertension. Ir J Med Sci. 2022;191(6):2549-57. DOI: 10.1007/s11845-021-02870-2. PMID: 35000115.
Symonides B, Kwiatkowska-Stawiarczyk M, Lewandowski J, Małyszko JS, Małyszko J. Resistant and apparently resistant hypertension in peritoneally dialyzed patients. J Clin Med. 2025;14(1):218. DOI: 10.3390/jcm14010218. PMID: 39797299.
Culha Y, Gülmez Ö, Başok Bİ, İşman FK, Oğuz A. Etiology in resistant hypertension. Anatol Curr Med J. 2024;6(3):232-9. DOI: 10.38053/acmj.1455488.
Azizi M, Lorthioir A, Amar L. Resistant hypertension. In: Hypertension. Elsevier; 2024. P. 542-55. DOI: 10.1016/b978-0-323-88369-6.00047-5.
Serrano PdL, Badia BdML, Barile JP, Mendes PM, Cavalheiro RBR, Peixoto KO, et al. Acute hepatic porphyria should be included in the diagnostic work-up of patients with resistant hypertension or suspected secondary hypertension. Med Sci. 2025;13(1):14. DOI: 10.3390/medsci13010014. PMID: 39982239.
Jónsson KB, Guðmundsson EO, Sigurðardóttir M, Jónsson JJ, Sigurjónsdóttir HÁ. Resistant hypertension – pheochromocytoma. Laeknabladid [The Icelandic Medical Journal]. 2023;109(3):141-5. DOI: 10.17992/lbl.2023.03.735. PMID: 36856470. [In Icelandic].
Dotsenko NY, Malynovska OY, Herasymenko LV, Shekhunova IO, Boiev SS, Molodan OV. Diagnosis, treatment and management of hypertension in Ukraine: survey of doctors. Mod Med Technol. 2022;4(55):13-20. DOI: 10.34287/mmt.4(55).2022.3. [In Ukrainian].
Milošević M, Otašević P. Treatment-resistant hypertension. Arh Farm. 2022;72(1):1-19. DOI: 10.5937/arhfarm72-34248.
Akram MZ, Mansoor K, Rasheed K, Maken GR, Faheem M, Mujahid M. Treatment-resistant hypertension in individuals of high BMI. Pak Armed Forces Med J. 2023;73(1):147-50. DOI: 10.51253/pafmj.v73i1.8280.
van den Born BJH, Bejan-Angoulvant T, Pengo MF, Mahfoud F, Sudano I, Hanssen H, Parati G. Targets for treatment and optimal strategies for managing hypertension in 2025: indications for clinical practice from recent hypertension guidelines. Eur J Prev Cardiol. 2026;33(7):1033-44. DOI: 10.1093/eurjpc/zwaf610. PMID: 40985288.
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. DOI: 10.1542/peds.2017-1904. PMID: 28827377.
Young WF. Secondary hypertension: primary hyperaldosteronism and mineralocorticoid excess states. In: Hypertension. Elsevier; 2024. P. 174-86. DOI: 10.1016/b978-0-323-88369-6.00014-1.
Munoz-Moreno JM, Gamarra-Valverde NN, Muedas-Porras G, Nombera-Aznarán M, Aguilar-Figueroa F, Gulati M. Diagnostic and therapeutic approach to the major secondary causes of arterial hypertension in young adults: a narrative review. Cardiol Rev. 2024. DOI: 10.1097/CRD.0000000000000805. PMID: 39729595.
Oberhoffer FS, Li P, Jakob A, Dalla-Pozza R, Haas NA, Mandilaras G. Energy drinks: effects on blood pressure and heart rate in children and teenagers. A randomized trial. Front Cardiovasc Med. 2022;9:862041. DOI: 10.3389/fcvm.2022.862041. PMID: 35387431.
Tzvi-Behr S, Greenstein LB, Ben-Shalom E, Frishberg Y, Cohen SO. Associations between prematurity, birthweight, and adolescence blood pressure in a nationwide cohort. Kidney Int Rep. 2024;9(5):1228-35. DOI: 10.1016/j.ekir.2024.02.1437. PMID: 38707822.
Venkatesh KK, Perak AM, Wu J, Catalano P, Josefson JL, Costantine MM, et al. Impact of hypertensive disorders of pregnancy and gestational diabetes mellitus on offspring cardiovascular health in early adolescence. Am J Obstet Gynecol. 2025;232(2):218.e1-12. DOI: 10.1016/j.ajog.2024.04.037. PMID: 38703941.
Jiang X, Jiang W, Zhu Y, Zhang H, Wang Z, Tang M, et al. Influence of body mass index on blood pressure in children and adolescents: a cross-sectional school-based study. BMC Public Health. 2025;25(1):4286. DOI: 10.1186/s12889-025-25463-5. PMID: 41436984.
Kogon AJ, Maqsood AM, LoGuidice J, Amaral S, Meyers K, Mitchell JA. Sleep duration and blood pressure in youth referred for elevated blood pressure evaluation. Pediatrics. 2024;154(1):e2023062940. DOI: 10.1542/peds.2023-062940. PMID: 38887814.
Ong J, Roem J, Ducharme-Smith K, Vizthum D, Lu M, Agrawal P, et al. Association of sodium and sugar-sweetened beverage intake with cardiovascular disease risk factors in adolescents and young adults with obesity. Clin Pediatr (Phila). 2024;63(5):669-79. DOI: 10.1177/00099228231186666. PMID: 37477185.
Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021;144(15):1212-26. DOI: 10.1161/CIRCULATIONAHA.121.055329. PMID: 34565172.
Paton JFR, Ratcliffe L, Hering D, Wolf J, Sobotka PA, Narkiewicz K. Revelations about carotid body function through its pathological role in resistant hypertension. Curr Hypertens Rep. 2013;15(4):273-80. DOI: 10.1007/s11906-013-0366-z. PMID: 23828147.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

